SCHEMBL384593

SCHEMBL384593

O=C(O)c1ccccc1Nc1cccc(Br)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FABP4 P15090 2/20 0.65
TAS2R14 Q9NYV8 6/20 0.62
PTGS1 P23219 2/20 0.62
AKR1C3 P42330 2/20 0.62
AKR1C2 P52895 2/20 0.62
PTGS2 P35354 1/20 0.62
CTSV O60911 1/20 0.57
CTSL P07711 1/20 0.57
MPO P05164 1/20 0.57
TTR P02766 1/20 0.55
SIRT2 Q8IXJ6 1/20 0.54
SIRT1 Q96EB6 1/20 0.54
GRIK1 P39086 2/20 0.53
GRIK2 Q13002 1/20 0.53
ALDH1A1 P00352 2/20 0.51
P2RX1 P51575 1/20 0.51
HTT P42858 1/20 0.51
NPC1 O15118 1/20 0.51
RAB9A P51151 1/20 0.51
MAPK8 P45983 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7572551 0.89 CXCR2 (0.63) FABP4TAS2R14PTGS1AKR1C3AKR1C2
SCHEMBL338231 0.86 P2RX1 (0.62) SIRT2SIRT1ALDH1A1P2RX1HTT
SCHEMBL28660772 0.83 MAPT (0.69) PTGS2SIRT2SIRT1ALDH1A1P2RX1
Fenamic Acid SCHEMBL25828 0.82 FABP4 (0.92) FABP4TAS2R14PTGS1AKR1C3AKR1C2
Fenamic Acid SCHEMBL29622832 0.82 FABP4 (0.92) FABP4TAS2R14PTGS1AKR1C3AKR1C2
SCHEMBL15673372 0.82 SIRT2 (0.77) FABP4TAS2R14PTGS1AKR1C3AKR1C2
SCHEMBL2294168 0.82 AKR1C3 (0.67) FABP4TAS2R14PTGS1AKR1C3AKR1C2
SCHEMBL9719838 0.82 FABP4 (0.67) FABP4TAS2R14PTGS1AKR1C3AKR1C2
SCHEMBL383535 0.82 GRIK1 (0.74) AKR1C3AKR1C2MPOGRIK1GRIK2
SCHEMBL15397409 0.82 AKR1C3 (0.60) AKR1C3AKR1C2MPOGRIK1GRIK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130310411-A1 NOVEL ACRIDINE DERIVATIVES PHARMINOX LIMITED (GB) 2013-11-21 US disclosed
EP-2621929-A1 NOVEL ACRIDINE DERIVATIVES Pharminox Limited (GB) 2013-08-07 EP disclosed
WO-2012042265-A1 NOVEL ACRIDINE DERIVATIVES PHARMINOX LIMITED (GB) 2012-04-05 WO disclosed
EP-1330456-B8 N8,N13 -DISUBSTITUTED QUINO[4,3,2-KL]ACRIDINIUM SALTS AS THERAPEUTIC AGENTS CANCER REC TECH LTD (GB) 2012-02-08 EP disclosed
EP-1330456-B9 N8,N13 -DISUBSTITUTED QUINO[4,3,2-KL]ACRIDINIUM SALTS AS THERAPEUTIC AGENTS CANCER REC TECH LTD (GB) 2012-01-25 EP disclosed
EP-1330456-B9 N8,N13 -DISUBSTITUTED QUINO[4,3,2-KL]ACRIDINIUM SALTS AS THERAPEUTIC AGENTS CANCER REC TECH LTD (GB) 2012-01-25 EP disclosed
EP-1330456-B1 N8,N13 -DISUBSTITUTED QUINO[4,3,2-KL]ACRIDINIUM SALTS AS THERAPEUTIC AGENTS CANCER REC TECH LTD (GB) 2011-06-15 EP disclosed
EP-1330456-B1 N8,N13 -DISUBSTITUTED QUINO[4,3,2-KL]ACRIDINIUM SALTS AS THERAPEUTIC AGENTS CANCER REC TECH LTD (GB) 2011-06-15 EP disclosed
US-7115619-B2 N8, N13 -disubstituted quino[4,3,2-kl]acridinium salts as therapeutic agents CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2006-10-03 US disclosed
US-20040063739-A1 N8, n13 -disubstituted quino[4,3,2-kl]acridinium salts as therapeutic agents CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2004-04-01 US disclosed
EP-1330456-A2 N8,N13 -DISUBSTITUTED QUINO 4,3,2-KL]ACRIDINIUM SALTS AS THERAPEUTIC AGENTS Cancer Research Technology Limited (GB) 2003-07-30 EP disclosed
WO-2002030932-A2 N8,N13-DISUBSTITUTED QUINO[4,3,2-KL]ACRIDINIUM SALTS AS THERAPEUTIC AGENTS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2002-04-18 WO disclosed
US-4168312-A Quinolone derivatives MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1979-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130310411-A1 NOVEL ACRIDINE DERIVATIVES TERT, NAT10, POT1 FABP4 4106/4885TAS2R14 3547/4885PTGS1 2166/4885
US-20040063739-A1 N8, n13 -disubstituted quino[4,3,2-kl]acridinium salts as therapeutic agents TERT, MKI67, NQO2 FABP4 4772/4885TAS2R14 2367/4885PTGS1 3003/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.